Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

Docetaxel chemotherapy is a standard treatment option for metastatic castrate resistant prostate cancer (mCRPC) patients. To date, the genomic perturbations underlying the emergence of resistance in mCRPC patients during chemotherapy treatment have not been fully characterized. Previous studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Winston, Zheng, Tiantian, Wang, Amy, Roacho, Joanna, Thao, Seng, Du, Pan, Jia, Shidong, Yu, Jianjun, King, Bonnie L., Kohli, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933498/
https://www.ncbi.nlm.nih.gov/pubmed/35304525
http://dx.doi.org/10.1038/s41598-022-08520-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933498/
https://www.ncbi.nlm.nih.gov/pubmed/35304525
http://dx.doi.org/10.1038/s41598-022-08520-6

Ejemplares similares